Literature DB >> 17459933

DNA immunization with plasmids encoding fusion and nucleocapsid proteins of bovine respiratory syncytial virus induces a strong cell-mediated immunity and protects calves against challenge.

Mathieu Boxus1, Marylène Tignon, Stefan Roels, Jean-François Toussaint, Karl Walravens, Marie-Ange Benoit, Philippe Coppe, Jean-Jacques Letesson, Carine Letellier, Pierre Kerkhofs.   

Abstract

Respiratory syncytial viruses (RSV) are one of the most important respiratory pathogens of humans and cattle, and there is currently no safe and effective vaccine prophylaxis. In this study, we designed two codon-optimized plasmids encoding the bovine RSV fusion (F) and nucleocapsid (N) proteins and assessed their immunogenicity in young calves. Two administrations of both plasmids elicited low antibody levels but primed a strong cell-mediated immunity characterized by lymphoproliferative response and gamma interferon production in vitro and in vivo. Interestingly, this strong cellular response drastically reduced viral replication, clinical signs, and pulmonary lesions after a highly virulent challenge. Moreover, calves that were further vaccinated with a killed-virus vaccine developed high levels of neutralizing antibody and were fully protected following challenge. These results indicate that DNA vaccination could be a promising alternative to the classical vaccines against RSV in cattle and could therefore open perspectives for vaccinating young infants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17459933      PMCID: PMC1933320          DOI: 10.1128/JVI.00502-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation.

Authors:  G Shaw; R Kamen
Journal:  Cell       Date:  1986-08-29       Impact factor: 41.582

2.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

Review 3.  An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs.

Authors:  M Kozak
Journal:  Nucleic Acids Res       Date:  1987-10-26       Impact factor: 16.971

4.  Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement.

Authors:  D A Tristram; R C Welliver; D A Hogerman; S W Hildreth; P Paradiso
Journal:  Vaccine       Date:  1994-05       Impact factor: 3.641

Review 5.  Respiratory syncytial virus. Brief review.

Authors:  E J Stott; G Taylor
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

6.  Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10.

Authors:  M Connors; N A Giese; A B Kulkarni; C Y Firestone; H C Morse; B R Murphy
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

Review 7.  Respiratory syncytial virus infections in human beings and in cattle.

Authors:  W H Van der Poel; A Brand; J A Kramps; J T Van Oirschot
Journal:  J Infect       Date:  1994-09       Impact factor: 6.072

8.  In vitro expression of full-length and truncated bovine respiratory syncytial virus G proteins and their antibody responses in BALB/c mice.

Authors:  Ryan P Brady; Christina L Topliff; Clayton L Kelling
Journal:  Vaccine       Date:  2004-09-09       Impact factor: 3.641

9.  Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old.

Authors:  D A Tristram; R C Welliver; C K Mohar; D A Hogerman; S W Hildreth; P Paradiso
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

10.  Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus.

Authors:  M J Cannon; P J Openshaw; B A Askonas
Journal:  J Exp Med       Date:  1988-09-01       Impact factor: 14.307

View more
  6 in total

1.  Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination.

Authors:  Elaine M Castilow; Steven M Varga
Journal:  Future Virol       Date:  2008       Impact factor: 1.831

2.  Nucleoprotein nanostructures combined with adjuvants adapted to the neonatal immune context: a candidate mucosal RSV vaccine.

Authors:  Aude Remot; Xavier Roux; Catherine Dubuquoy; Jenna Fix; Stephan Bouet; Mohammed Moudjou; Jean-François Eléouët; Sabine Riffault; Agnès Petit-Camurdan
Journal:  PLoS One       Date:  2012-05-24       Impact factor: 3.240

3.  Sub-nucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus.

Authors:  Xavier Roux; Catherine Dubuquoy; Guillaume Durand; Thi-Lan Tran-Tolla; Nathalie Castagné; Julie Bernard; Agnès Petit-Camurdan; Jean-François Eléouët; Sabine Riffault
Journal:  PLoS One       Date:  2008-03-12       Impact factor: 3.240

4.  A new subunit vaccine based on nucleoprotein nanoparticles confers partial clinical and virological protection in calves against bovine respiratory syncytial virus.

Authors:  Sabine Riffault; Gilles Meyer; Martine Deplanche; Catherine Dubuquoy; Guillaume Durand; Marion Soulestin; Nathalie Castagné; Julie Bernard; Philippe Bernardet; Virginie Dubosclard; Florence Bernex; Agnès Petit-Camurdan; Sébastien Deville; Isabelle Schwartz-Cornil; Jean-François Eléouët
Journal:  Vaccine       Date:  2010-03-20       Impact factor: 3.641

5.  Gene optimization leads to robust expression of human respiratory syncytial virus nucleoprotein and phosphoprotein in human cells and induction of humoral immunity in mice.

Authors:  Fernando M Simabuco; Rodrigo E Tamura; Cassiano Carromeu; Luis E Farinha-Arcieri; Armando M Ventura
Journal:  J Virol Methods       Date:  2009-02-04       Impact factor: 2.014

6.  Vaccination of calves using the BRSV nucleocapsid protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects the lungs against BRSV replication and pathology.

Authors:  Carine Letellier; Mathieu Boxus; Laurent Rosar; Jean-François Toussaint; Karl Walravens; Stefan Roels; Gilles Meyer; Jean-Jacques Letesson; Pierre Kerkhofs
Journal:  Vaccine       Date:  2008-07-21       Impact factor: 3.641

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.